WASHINGTON -- Children who are healthy but abnormally short will be able to have injections of growth hormone in hopes of gaining 1 to 3 more inches of height, the Food and Drug Administration said ...

Ascendis Pharma A/S (NASDAQ:ASND) executives highlighted topline Week 52 results from the company’s Phase 2 COACH trial, ...

The FDA approved long-acting injectable somatrogon (Ngenla) for pediatric human growth hormone deficiency, developers Pfizer and OPKO Health announced this week. Somatrogon is indicated for children ...

NEW YORK (Reuters Health) - For short kids, treatment with growth hormone leads to height increases of up to 7.5 centimeters (just under 3 inches), but the majority of these children will remain ...

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a ...

(Reuters) -The U.S. Food and Drug Administration has approved Pfizer Inc and partner OPKO Health Inc's treatment for growth hormone deficiency in children, the companies said on Wednesday. The ...

Growth hormone deficiency is a rare, treatable condition that causes short stature in children. It is less common in adults. Growth hormone deficiency (GHD) occurs when your pituitary gland doesn’t ...

Children with growth disturbance could be offered a new weekly treatment as an alternative to daily injections. The National Institute for Health and Care Excellence (NICE) has recommended somatrogon ...

A comparison of morning and evening growth hormone injection schedules in children with growth disorders showed no significant differences in sleep-wake patterns, sleep duration, or daytime activity, ...